Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.66 |
| ▸ | PIM1 | P11309 | 2/20 | 0.65 |
| ▸ | CDC7 | O00311 | 1/20 | 0.65 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.65 |
| ▸ | CDK2 | P24941 | 1/20 | 0.65 |
| ▸ | GSK3B | P49841 | 1/20 | 0.65 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.65 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.65 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5618982 | 0.90 | PIM1 (0.64) | DPP4PIM1CDC7MAP4K4CDK2 | |
| SCHEMBL11750772 | 0.83 | PIM1 (0.75) | DPP4PIM1CDC7MAP4K4CDK2 | |
| SCHEMBL11539600 | 0.81 | HSD17B10 (0.74) | DPP4PIM1CDC7MAP4K4CDK2 | |
| SCHEMBL5619103 | 0.81 | PIM1 (0.67) | DPP4PIM1CDC7MAP4K4CDK2 | |
| SCHEMBL4781880 | 0.81 | PIM1 (0.67) | DPP4PIM1CDC7MAP4K4CDK2 | |
| SCHEMBL5618934 | 0.81 | DPP4 (0.62) | DPP4PIM1CDC7MAP4K4CDK2 | |
| SCHEMBL18126720 | 0.79 | HSD17B10 (0.67) | DPP4PIM1CDC7MAP4K4CDK2 | |
| SCHEMBL5619137 | 0.79 | DPP4 (0.66) | DPP4PIM1CDC7MAP4K4CDK2 | |
| SCHEMBL5619274 | 0.78 | PIM1 (0.63) | DPP4PIM1CDC7MAP4K4CDK2 | |
| SCHEMBL5618927 | 0.78 | PIM1 (0.63) | DPP4PIM1CDC7MAP4K4CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173033-B2 | Nitrogen-containing heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-20060173009-A1 | Agent inducing increase in bone mass | ASTELLAS PHARMA INC. (JP) | 2006-08-03 | — | — | US | disclosed |
| EP-1640010-A1 | AGENT INDUCING INCREASE IN BONE MASS | Astellas Pharma Inc. (JP) | 2006-03-29 | — | — | EP | disclosed |
| US-20050261297-A1 | Nitrogen-containing heterocyclic compound | YAMANOUCHI PHARMACEUTICAL CO., LTD | 2005-11-24 | — | — | US | disclosed |
| US-20050096322-A1 | Nitrogen-containing heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2005-05-05 | — | — | US | disclosed |
| EP-1481977-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096322-A1 | Nitrogen-containing heterocyclic compound | BMP2, BMP1, BMP4 | DPP4 1336/4885PIM1 4018/4885CDC7 3312/4885 |
| US-20050261297-A1 | Nitrogen-containing heterocyclic compound | BMP2, BMP1, BMP4 | DPP4 1336/4885PIM1 4018/4885CDC7 3312/4885 |
| US-20060173009-A1 | Agent inducing increase in bone mass | SOST, CALCB, BMP4 | DPP4 576/4885PIM1 1851/4885CDC7 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.